ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P ASX 200
8,296.20
-0.32%
S&P ASX All Technology
4,030.80
-1.66%
Brent Oil
73.935
0.00%
US Dollar vs AUD
1.57356
0.00%
Bitcoin
96,440.86
0.31%
Pepperstone
Advertisement
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Recursion Pharmaceuticals Inc (RXRX) Share Price

Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals Inc (RXRX)

NASDAQ
9.28
-1.07
(-10.34%)
Closed 22 February 8:00AM
Delayed by 15 minutes
9.27
-0.01
(-0.11%)
After Hours: 11:59AM
Delayed by 15 minutes

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Key stats and details

Current Price
9.27
Bid
9.26
Offer
9.31
Volume
31,524,155
9.15 Day's Range 10.60
5.60 52 Week Range 15.74
Market Cap
2.657B
Previous Close
10.35
Open
10.38
Last Trade
1
@
9.27
Last Trade Time
Financial Volume
US$ 307,275,097
VWAP
9.7473
Average Volume (3m)
21,866,155
Shares Outstanding
286,640,833
Dividend Yield
-
PE Ratio
-8.10
Earnings Per Share (EPS)
-1.14
Revenue
44.58M
Net Profit
-328.07M

About Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. It is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery... Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. It is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery. Show more

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Website
www.recursion.com
Headquarters
Wilmington, Delaware, USA
Founded
-
Recursion Pharmaceuticals Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker RXRX. The last closing price for Recursion Pharmaceuticals was US$10.35. Over the last year, Recursion Pharmaceuticals shares have traded in a share price range of US$ 5.60 to US$ 15.74.

Recursion Pharmaceuticals currently has 286,640,833 shares in issue. The market capitalisation of Recursion Pharmaceuticals is US$2.97 billion. Recursion Pharmaceuticals has a price to earnings ratio (PE ratio) of -8.10.

Ask ADVFN Intelligence (AI)

Recursion Pharmaceuticals (RXRX) Options Flow Summary

RXRX Options Flow

Overall Flow

Bullish

Net Premium

916k

Calls / Puts

238.10%

Buys / Sells

85.29%

OTM / ITM

42.00%

Sweeps Ratio

0.00%

RXRX Latest News

More News

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
21 February 2025
RXRX (-10.34%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
21 February 2025
RXRX (-10.34%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
08 February 2025
RXRX (-10.34%)

Form 144 - Report of proposed sale of securities
Edgar (US Regulatory)
07 February 2025
RXRX (-10.34%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
06 February 2025
RXRX (-10.34%)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.11.090512540899.1712.369.046041465710.61135499CS
41.6321.3350785347.6412.366.72318069308.80873288CS
122.7742.61538461546.512.365.93218661558.01120852CS
262.129.28870292897.1712.365.6128742347.62259326CS
52-2.93-24.016393442612.215.745.692921868.16954538CS
156-0.79-7.8528827037810.0616.7454.5448836608.69672938CS
260-20.73-69.13042.814.5439983709.30377665CS

RXRX - Frequently Asked Questions (FAQ)

What is the current Recursion Pharmaceuticals share price?
The current share price of Recursion Pharmaceuticals is US$ 9.27
How many Recursion Pharmaceuticals shares are in issue?
Recursion Pharmaceuticals has 286,640,833 shares in issue
What is the market cap of Recursion Pharmaceuticals?
The market capitalisation of Recursion Pharmaceuticals is USD 2.97B
What is the 1 year trading range for Recursion Pharmaceuticals share price?
Recursion Pharmaceuticals has traded in the range of US$ 5.60 to US$ 15.74 during the past year
What is the PE ratio of Recursion Pharmaceuticals?
The price to earnings ratio of Recursion Pharmaceuticals is -8.1
What is the cash to sales ratio of Recursion Pharmaceuticals?
The cash to sales ratio of Recursion Pharmaceuticals is 59.61
What is the reporting currency for Recursion Pharmaceuticals?
Recursion Pharmaceuticals reports financial results in USD
What is the latest annual turnover for Recursion Pharmaceuticals?
The latest annual turnover of Recursion Pharmaceuticals is USD 44.58M
What is the latest annual profit for Recursion Pharmaceuticals?
The latest annual profit of Recursion Pharmaceuticals is USD -328.07M
What is the registered address of Recursion Pharmaceuticals?
The registered address for Recursion Pharmaceuticals is 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
What is the Recursion Pharmaceuticals website address?
The website address for Recursion Pharmaceuticals is www.recursion.com
Which industry sector does Recursion Pharmaceuticals operate in?
Recursion Pharmaceuticals operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
MLGOMicroAlgo Inc
US$ 6.3767
(454.50%)
531.54M
BOXLBoxlight Corporation
US$ 3.1099
(51.70%)
1.84M
GDEVGDEV Inc
US$ 20.90
(46.56%)
264.44k
IVVDInvivyd Inc
US$ 1.7501
(44.64%)
37.75M
UPCUniverse Pharmaceuticals Inc
US$ 0.2003
(40.56%)
420.21M
DOYUDouYu International Holdings Ltd
US$ 7.19
(-55.31%)
1.28M
MNDRMobile health Network Solutions
US$ 0.5048
(-46.29%)
18.61M
BLUEbluebird bio Inc
US$ 4.09
(-41.90%)
5.44M
FLDFold Holdings Inc
US$ 6.95
(-37.39%)
488.54k
GCLGCL Global Holdings Ltd
US$ 3.83
(-31.48%)
635.26k
MLGOMicroAlgo Inc
US$ 6.3767
(454.50%)
531.54M
UPCUniverse Pharmaceuticals Inc
US$ 0.2003
(40.56%)
420.21M
ADTXAditxt Inc
US$ 0.0922
(-22.39%)
278.25M
NVDANVIDIA Corporation
US$ 134.43
(-4.05%)
228.14M
HOLOMicroCloud Hologram Inc
US$ 1.565
(31.51%)
190.81M

RXRX Discussion

View Posts
bwrbad bwrbad 2 days ago
Big volume -- could be green EOD
👍️0
bwrbad bwrbad 4 days ago
once cross 36 - it is open sky.
everyday dips are the advantage point
buying the $200 -$300 /sh stock of 2025 at $11 -$36
👍️0
bwrbad bwrbad 4 days ago
could move $3 -$5 today
👍️0
bwrbad bwrbad 6 days ago
https://x.com/RecursionChris/status/1747265218437349847
👍️0
TucsonPhil TucsonPhil 1 week ago
I'd wager that undisclosed information is at play, but that wouldn't be legal, so couldn't possibly be the case.
👍️0
3antar 3antar 1 week ago
So why do you think it keeps going higher! 
👍️0
bwrbad bwrbad 1 week ago
blindfold buy at 20 - 30 then the jump 100 - 200
👍️0
bwrbad bwrbad 1 week ago
RXRX
👍️0
TucsonPhil TucsonPhil 1 week ago
They announce a mixed shelf (dilution), and the price spikes?
👍️0
bwrbad bwrbad 1 week ago
RXRX just started little little sprinting step before planting the pole and jump over that record high pole vault bar
👍 1
bwrbad bwrbad 1 week ago
invest - - soon --- before out of reach.
👍️0
bwrbad bwrbad 1 week ago
this is a stock will gain 200-300% in a single day-- but today - no - it will go back to +3c or -3c in 1h
👍️0
TucsonPhil TucsonPhil 2 weeks ago
This level of result, will make this company fly:

https://www.globenewswire.com/news-release/2025/02/05/3021646/0/en/Recursion-Presents-Phase-2-Data-for-REC-994-in-CCM-in-Late-Breaking-Oral-Presentation-at-the-International-Stroke-Conference.html
👍️ 1
bwrbad bwrbad 2 weeks ago
generative AI in making medical miracle
👍️0
bwrbad bwrbad 2 weeks ago
REC-994 MRI-based brainstem lesion volume reduction : place a $M maker brick now
👍️0
bwrbad bwrbad 3 weeks ago
70 institution 30 public--that's how RXRX drug working now
👍️0
bwrbad bwrbad 3 weeks ago
YouTube influencer position - write or call cGibson@recursion.com
👍️0
TucsonPhil TucsonPhil 3 weeks ago
Exactly, when we see the lending fees start to rise, then I will buy more. Brokers always make money, even when investors lose.
👍️0
bwrbad bwrbad 3 weeks ago
they all do etard fidal TDA, but that gives the opportunity to buy low. This RxRx defines the future of MED world in AI stage- just buying little little within affordability. definitively it will grow like MSTF GOOG AAPL NVDA AMZN.., All drug lords pfizer, j&j eli, merck roche AZ BMS are lining up behind, just give few months to a year for first $100
👍️0
TucsonPhil TucsonPhil 3 weeks ago
Fidelity is loaning shares to shorts.
👍️0
bwrbad bwrbad 3 weeks ago
next piece of clinical update will take it above 20 and after that it is in different league.
👍️0
bwrbad bwrbad 4 weeks ago
Sure looks like early days of ISRG ILMN,
👍️0
TucsonPhil TucsonPhil 4 weeks ago
Nvidia invested $50M in this company. ARK is a holder. This will be huge, once their first find gets FDA approval, and proof of concept is secured.
👍️ 1
bwrbad bwrbad 4 weeks ago
interesting no posters in this
future $200 - $300 stock, and that future not far - see the quality of clinical data, target diseases, and the time it took to reach there - not standard 20 ys but 3y to ph3 and a large advancing failure resistant AI powered pipeline
👍️0
bwrbad bwrbad 4 weeks ago
change of heart -going up.
👍️0
bwrbad bwrbad 4 weeks ago
rxrx WORLD
👍️0
bwrbad bwrbad 1 month ago
promised to accumulate 10k shares before Q end and hold for years. predict this issue never go BK, do RS, and one day go beyond 200+ like established big cap security issues.
👍️0
bwrbad bwrbad 1 month ago
bandwagon
👍️0
bwrbad bwrbad 1 month ago
believe in miracle ----- come to RXRX------
👍️0
TucsonPhil TucsonPhil 1 month ago
Looks like Lilly is late to the party.

https://www.statnews.com/2025/01/10/eli-lilly-andreessen-horowitz-500-million-venture-fund-ai-focus/
👍️0
bwrbad bwrbad 1 month ago
cursion-re-cursion in flame after FDA REC 3565 blessings
👍️0
bwrbad bwrbad 2 months ago
Gibson🤢🥵🥶😷Gibson
👍️0
bwrbad bwrbad 2 months ago
baby nvda
👍 1
bwrbad bwrbad 2 months ago
balding haircut at RXRX
👍️0
Monksdream Monksdream 2 months ago
RXRX, under $7
👍️0
bwrbad bwrbad 2 months ago
out for now, let CEO work his magic if he has one under his sleeve
👍️0
bwrbad bwrbad 2 months ago
is something wrong with RxRx, it looked promising based on what said to public. but something not right. ground shaken up. - like trouble.
what wrong with the CEO. if this continues that is bad sign for future of the company and the CEO.
👍️0
bwrbad bwrbad 2 months ago
RXRX
👍️0
bwrbad bwrbad 2 months ago
RxRx partnership: GOOG NVDA MSFT Roche/Genentech Bayer Bristol Myers Squibb Sanofi Merck ......
👍 1
bwrbad bwrbad 2 months ago
RxRx M&A: Valence –Cyclica - Exscientia
Valence – a leader in generative AI and deep learning models
Cyclica - a deep learning engine that predicts the polypharmacology of small molecules in drug discovery.
Exscientia - AI-driven precision medicine
RXRX - Regenerative AI - TechBio powerhouse
undergoing post merger reorganization, some job cuts
enough cash to fund through 2027
Ark Q3 2024 Stake: $215.9 million
Hedge Fund Investors Q3 2024:: 16
more than ten drugs in trials.
👍️0
bwrbad bwrbad 2 months ago
market up big and RxRx ignored,
if quantum computing which is 7-10 years away getting attention now, then this should be in the rocket heading for stratosphere.
👍️0
TucsonPhil TucsonPhil 2 months ago
RXRX seeing some promising results in early trials. Proof of concept will solidify belief in the platform.

If cost of trials can be reduced, by less attrition of candidates, then they should see more licensing agreements, and funding, from pharma companies IMO.
👍️ 1
bwrbad bwrbad 2 months ago
Revenue (ttm) 65.18M; Quarterly Revenue Growth (yoy) 147.60%
Total Cash (mrq) 427.65M; Total Debt (mrq) 90.62M
Shares Outstanding 6 388.94M; Float 8 252.42M
clinical trial : REC-994 in Phase 2, REC-2282 in Phase 2/3; few other in phase 1 and 2, all in less than 2 year not 15-18 years (conventional).

% Held by Institutions 1 69.40% Shares Short (Nov 15, 2024) 4 64.57M 25%
👍️ 1
JJ8 JJ8 2 months ago
Rxrx share price Long Tail Up since 06 Dec 2024.
👍️0
paperman paperman 2 months ago
Phase 1 news expected tonight at conference.
👍️0
paperman paperman 2 months ago
Phase 1 news expected tonight at conference.
👍️0
bwrbad bwrbad 2 months ago
this is one magnificent AI drug discovery platform - be household name like google tesla Microsoft ...
👍️0
JJ8 JJ8 3 months ago
Bought it yesterday at $6.60

Today it's up about 22%.

Same story with 2 other stocks and they all go up today more than 20%!

Whoa! IN CREDIBLE!
👍️0
TucsonPhil TucsonPhil 3 months ago
Agreed, but there will be wild swings, until they get their footing with clinical trials proving the concept works. Trade it until then, and keep one foot in the door for surprise announcements.
👍️0
bwrbad bwrbad 3 months ago
RxRx going to be top player in future pharma drug discovery
👍️0

Your Recent History

NASDAQ
RXRX
Recursion Pharmaceuticals
LSE
TTG
Tt Electronics
BIT
UB8LJ5
Unicredit Bank
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads